Satralizumab Continues to Display Long-Term Efficacy in AQP4-IgG-Seropositive NMOSD.

Published Date: 15 Oct 2023

The SAkuraMoon study's annual relapse rate was consistently low in patients receiving satralizumab, according to a recent analysis, and a sizable portion of patients did not experience mild relapses, severe relapses, or worsening disability.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?

2.

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

3.

For patients with prostate cancer, long-term follow-up helps identify treatment side effects.

4.

Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?

5.

Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot